Abstract
Transoral Robotic Surgery (TORS) was reported as being one of the most minimally invasive surgery (MIS) procedures available by the University of Pennsylvania in 2005. TORS has increasingly been employed in the treatment of oropharyngeal carcinoma throughout the world on account of the various advantages including superior surgical manipulation of the oropharyngeal tissue, excellent visualization and accurate resection. We investigated 16 cases relating to TORS and oropharyngeal carcinoma from a total of 78 English academic documents. We analyzed data from 595 patients who were treated with TORS from 2005 to 2013. Patient numbers of T1, T2, T3 and T4 were 243, 296, 38 and 18, respectively. The number of N0, N1, N2 and N3 were 168, 98,307 and 22, respectively. The mean hospital stay time was 5.3 days. In regard to margin status, the margin free rate was 93.1%. The percutaneous gastrostomy (PEG) tube dependency rate was 3.8%. Loco-regional recurrences and distant metastasis were reported at 3.0% and 2.8%, respectively. The two year overall survival rate was 80.6-100%, and 2 year disease free survival rate was 92-100%. We conclude that TORS is a safe and advantageous procedure for treating oropharyngeal carcinoma.
Keywords: Human papilloma virus (HPV), minimally invasive surgery (MIS), oropharyngeal carcinoma, transoral robotic surgery (TORS).
Current Cancer Therapy Reviews
Title:Epoch-making Treatment with Transoral Robotic Surgery for Oropharyngeal Carcinoma
Volume: 11 Issue: 1
Author(s): Akira Shimizu, Mamoru Suzuki, Suren Krishnan and Junkichi Yokoyama
Affiliation:
Keywords: Human papilloma virus (HPV), minimally invasive surgery (MIS), oropharyngeal carcinoma, transoral robotic surgery (TORS).
Abstract: Transoral Robotic Surgery (TORS) was reported as being one of the most minimally invasive surgery (MIS) procedures available by the University of Pennsylvania in 2005. TORS has increasingly been employed in the treatment of oropharyngeal carcinoma throughout the world on account of the various advantages including superior surgical manipulation of the oropharyngeal tissue, excellent visualization and accurate resection. We investigated 16 cases relating to TORS and oropharyngeal carcinoma from a total of 78 English academic documents. We analyzed data from 595 patients who were treated with TORS from 2005 to 2013. Patient numbers of T1, T2, T3 and T4 were 243, 296, 38 and 18, respectively. The number of N0, N1, N2 and N3 were 168, 98,307 and 22, respectively. The mean hospital stay time was 5.3 days. In regard to margin status, the margin free rate was 93.1%. The percutaneous gastrostomy (PEG) tube dependency rate was 3.8%. Loco-regional recurrences and distant metastasis were reported at 3.0% and 2.8%, respectively. The two year overall survival rate was 80.6-100%, and 2 year disease free survival rate was 92-100%. We conclude that TORS is a safe and advantageous procedure for treating oropharyngeal carcinoma.
Export Options
About this article
Cite this article as:
Shimizu Akira, Suzuki Mamoru, Krishnan Suren and Yokoyama Junkichi, Epoch-making Treatment with Transoral Robotic Surgery for Oropharyngeal Carcinoma, Current Cancer Therapy Reviews 2015; 11 (1) . https://dx.doi.org/10.2174/1573394711666150428002953
DOI https://dx.doi.org/10.2174/1573394711666150428002953 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Advancements in Lipid Nanoparticle Delivery Systems for mRNA Therapeutics
The thematic issue will focus on key areas such as lipid nanoparticles, mRNA therapeutics, drug delivery systems, nanotechnology in medicine, targeted therapy, non-viral vectors, precision medicine, and biomedical engineering.read more
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
FDG-PET/CT and SPECT/CT in Oncology
Current Medical Imaging Gene Therapy Using an Adenovirus Vector for Apoptosis-Related Genes is a Highly Effective Therapeutic Modality for Killing Glioma Cells
Current Gene Therapy Telomerase Inhibitors: Potential Anticancer Agents
Mini-Reviews in Organic Chemistry Radionuclide Imaging in Drug Development
Current Pharmaceutical Design Repurposing of Alexidine Dihydrochloride as an Apoptosis Initiator and Cell Cycle Inhibitor in Human Pancreatic Cancer
Anti-Cancer Agents in Medicinal Chemistry Methodological Aspects and Applications of In Vivo Imaging of Apoptosis in Oncology: An Illustrative Review
Current Medical Imaging Oncogenic Fusion Tyrosine Kinases as Molecular Targets for Anti-Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Inhibition of Hyaluronan Synthase-3 Decreases Subcutaneous Colon Cancer Growth by Increasing Apoptosis
Anti-Cancer Agents in Medicinal Chemistry Expression and Prognostic Relevance of GAGE1 and XAGE1 Cancer/Testis Antigens in Head and Neck Squamous Cell Carcinoma
Current Molecular Medicine Vitamin D3 and Vitamin D3 Analogues as an Adjunct to Cancer Chemotherapy and Radiotherapy
Current Medicinal Chemistry - Anti-Cancer Agents Comparison of Ultrasonography and Computed Tomography Features of Calcified Thyroid Nodules
Current Medical Imaging Metal Containing Cytostatics and Their Interaction with Cellular Thiol Compounds Causing Chemoresistance
Anti-Cancer Agents in Medicinal Chemistry New Ways to Improve Breast Cancer Therapy Targeting Specific Molecular Pathways
Current Cancer Therapy Reviews Potential Usage of ING Family Members in Cancer Diagnostics and Molecular Therapy
Current Drug Targets Development of Patents and Clinical Trials on Regenerative Therapy: Gene Therapy
Recent Patents on Regenerative Medicine Immunoregulatory and Effector Activities of Nitric Oxide and Reactive Nitrogen Species in Cancer
Current Medicinal Chemistry HLA Class I Expression, Tumor Escape and Cancer Progression
Current Cancer Therapy Reviews The Expression of Glutaminases and their Association with Clinicopathological Parameters in the Head and Neck Cancers
Current Cancer Drug Targets Immunological Aspects of the Prostate Gland and Related Diseases
Current Immunology Reviews (Discontinued) Crosstalk Between Epidermal Growth Factor Receptor- and Insulin-Like Growth Factor-1 Receptor Signaling: Implications for Cancer Therapy
Current Cancer Drug Targets